Gluetacs Therapeutics

A Shanghai biotech developing oral targeted protein degraders for oncology and immunology from paired molecular glue and bifunctional libraries.

Location: Shanghai, China

Website

1 model(1 Small molecule, 1 Protein)

Models (1)

AiPROTAC

Tsinghua University / Agency for Science, Technology and Research (A*STAR) / Gluetacs Therapeutics / Xuzhou Medical University / Central South University / China University of Mining and Technology / Jiangnan University / Sichuan University

Released March 2, 2025

——11

PROTAC degradation prediction from molecular graphs of the target, linker, and E3 ligase, combining cross-attention with contrastive learning.

Small moleculeProtein